Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $443,535 | 12 | 90.3% |
| Travel and Lodging | $46,827 | 11 | 9.5% |
| Food and Beverage | $1,045 | 6 | 0.2% |
| Unspecified | $0 | 11 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Thrombogenics, Inc. | $262,423 | 16 | $0 (2020) |
| EyePoint Pharmaceuticals US, Inc. | $228,984 | 24 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $59,439 | 4 | EyePoint Pharmaceuticals US, Inc. ($59,439) |
| 2023 | $86,500 | 6 | EyePoint Pharmaceuticals US, Inc. ($86,500) |
| 2022 | $82,596 | 5 | EyePoint Pharmaceuticals US, Inc. ($82,596) |
| 2021 | $0 | 2 | EyePoint Pharmaceuticals US, Inc. |
| 2020 | $20,056 | 7 | Thrombogenics, Inc. ($19,607) |
| 2019 | $73,905 | 6 | ThromboGenics, Inc. ($73,905) |
| 2018 | $71,650 | 7 | ThromboGenics, Inc. ($71,650) |
| 2017 | $97,262 | 3 | ThromboGenics, Inc. ($97,262) |
All Payment Transactions
40 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/01/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | Cash or cash equivalent | $3,616.89 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 03/27/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Consulting Fee | Cash or cash equivalent | $55,821.70 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 2024 | EyePoint Pharmaceuticals US, Inc. | — | — | — | $0.00 | Ownership |
| 2024 | EyePoint Pharmaceuticals US, Inc. | — | — | — | $0.00 | Ownership |
| 12/30/2023 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 | Consulting Fee | Cash or cash equivalent | $23,625.00 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 09/27/2023 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 | Consulting Fee | Cash or cash equivalent | $20,625.00 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 06/30/2023 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 | Consulting Fee | Cash or cash equivalent | $20,625.00 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 03/30/2023 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 | Consulting Fee | Cash or cash equivalent | $21,625.00 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 2023 | EyePoint Pharmaceuticals US, Inc. | — | — | — | $0.00 | Ownership |
| 2023 | EyePoint Pharmaceuticals US, Inc. | — | — | — | $0.00 | Ownership |
| 12/15/2022 | EyePoint Pharmaceuticals US, Inc. | DEXYCU (Drug), YUTIQ | Consulting Fee | Cash or cash equivalent | $82,000.00 | General |
| Category: Postoperative Inflammation | ||||||
| 12/13/2022 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $270.00 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 11/23/2022 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $326.05 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 2022 | EyePoint Pharmaceuticals US, Inc. | — | — | — | $0.00 | Ownership |
| 2022 | EyePoint Pharmaceuticals US, Inc. | — | — | — | $0.00 | Ownership |
| 2021 | EyePoint Pharmaceuticals US, Inc. | — | — | — | $0.00 | Ownership |
| 2021 | EyePoint Pharmaceuticals US, Inc. | — | — | — | $0.00 | Ownership |
| 02/20/2020 | EyePoint Pharmaceuticals US, Inc. | DEXYCU (Drug), YUTIQ | Food and Beverage | In-kind items and services | $75.09 | General |
| Category: Postoperative Inflammation | ||||||
| 02/20/2020 | EyePoint Pharmaceuticals US, Inc. | DEXYCU (Drug), YUTIQ | Food and Beverage | In-kind items and services | $74.04 | General |
| Category: Postoperative Inflammation | ||||||
| 02/19/2020 | EyePoint Pharmaceuticals US, Inc. | DEXYCU (Drug), YUTIQ | Food and Beverage | In-kind items and services | $240.23 | General |
| Category: Postoperative Inflammation | ||||||
| 02/19/2020 | EyePoint Pharmaceuticals US, Inc. | DEXYCU (Drug), YUTIQ | Food and Beverage | In-kind items and services | $59.55 | General |
| Category: Postoperative Inflammation | ||||||
| 01/21/2020 | Thrombogenics, Inc. | Jetrea (Drug) | Consulting Fee | Cash or cash equivalent | $19,606.74 | General |
| Category: Opthalmology | ||||||
| 2020 | EyePoint Pharmaceuticals US, Inc. | — | — | — | $0.00 | Ownership |
| 2020 | EyePoint Pharmaceuticals US, Inc. | — | — | — | $0.00 | Ownership |
| 06/18/2019 | ThromboGenics, Inc. | Jetrea (Drug) | Consulting Fee | Cash or cash equivalent | $19,606.74 | General |
| Category: Opthalmology | ||||||
About David Guyer
David Guyer is a Ophthalmology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2014. The National Provider Identifier (NPI) number assigned to this provider is 1467873760.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, David Guyer has received a total of $491,407 in payments from pharmaceutical and medical device companies, with $59,439 received in 2024. These payments were reported across 40 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($443,535).
Practice Information
- Specialty Ophthalmology
- Location New York, NY
- Active Since 01/04/2014
- Last Updated 01/04/2014
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1467873760
Products in Payments
- Jetrea (Drug) $262,423
- EYP-1901 $86,500
- DEXYCU (Drug) $82,449
- EYP-1901 (Drug) $59,439
- YUTIQ (Drug) $596.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in New York
Dr. Tsontcho Ianchulev, M.d. Mph, M.D. MPH
Ophthalmology — Payments: $21.4M
Dr. Nathan Radcliffe, M.d, M.D
Ophthalmology — Payments: $2.2M
Dr. Joshua Young, M.d, M.D
Ophthalmology — Payments: $805,605
Dr. Raymond Fong, M.d, M.D
Ophthalmology — Payments: $581,936
Joseph Panarelli, M.d, M.D
Ophthalmology — Payments: $525,201
Christopher Starr, Md, MD
Ophthalmology — Payments: $279,545